The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

It appears some investors may be coming round to the thinking of Ken Griffin, the billionaire founder of hedge fund Citadel, who recently warned that the "uncertainty and chaos" created by President ...

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.

Brand collaborations remain a popular tactic for challenger brands to reach new audiences. Bubble Skincare and Touchland will ...

We recently compiled a list of the Jim Cramer’s Game Plan: 17 Stocks in Focus. In this article, we are going to take a look ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

BofA analysts, in a note this month, said Nvidia's results will mark the "next important test for AI bulls," adding that the company's per-share profit "could have enough substance even if less sizzle ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) saw unusually-high trading volume on Friday after Bank of America raised their price target on the stock from $18.00 to $21.00. Bank of ...